British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults

作者：Abid R. Suddle, Helen Louise Reeves, Richard A Hubner, Aileen Marshall, Ian A.C. Rowe, DINA G. TINIAKOS, Stefan G. Hübscher, Mark P. Callaway, Dinesh kumar Sharma, Teik Choon See, M. Hawkins, Suzanne Ford‐Dunn, Sarah Selemani, Tim Meyer · 发表于：Gut · 年份：2024 · DOI：10.1136/gutjnl-2023-331695 · 被引用次数：70 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Colorectal Cancer Treatments and Studies、Gastric Cancer Management and Outcomes

Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.